Summary:

This study presents patient-reported outcomes from individuals with Charcot-Marie-Tooth (CMT) disease who used medical cannabis to manage chronic pain. Participants described notable improvements in pain severity, sleep quality, and overall function. The study underscores cannabis’ potential as a complementary therapy for neuropathic pain in rare neuromuscular conditions, with minimal side effects reported.

Key Takeaways:

• 91% of participants reported improved pain management with cannabis.
• Significant improvements in sleep and function.
• Cannabis was generally well-tolerated, with low incidence of adverse effects.

Real Isolates Relevance:

The study reflects the therapeutic potential of cannabinoid-based therapies—an area where Real Isolates’ standardized formulations and combustion-optimized extracts can be applied to support targeted pain relief in complex conditions like CMT.